Analgesics
Antiandrogens
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lactoferrin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Quercetin
Remdesivir
Vitamins

Other
Feedback
Home
Top
Results
Abstract
All bebtelovimab studies
Meta analysis
 
Feedback
Home
c19early.org COVID-19 treatment researchBebtelovimabBebtelovimab (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Hospitalization -27% Improvement Relative Risk Hospitalization (b) -2% Recovery time 25% no CI Viral load reduction, day 7 4% Viral load reduction, day 5 30% Viral load reduction, day 3 15% Viral clearance 39% primary Bebtelovimab  BLAZE-4  EARLY TREATMENT  RCT Is early treatment with bebtelovimab beneficial for COVID-19? RCT 714 patients in the USA (April - July 2021) Improved viral clearance with bebtelovimab (p<0.000001) c19early.org Dougan et al., medRxiv, March 2022 Favors bebtelovimab Favors control

Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19

Dougan et al., medRxiv, doi:10.1101/2022.03.10.22272100, BLAZE-4, NCT04634409
Mar 2022  
  Twitter
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
RCT showing improved viral clearance with bebtelovimab. Results refer to the placebo controlled portion of the trial.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron BQ.1.1 Planas.
This study includes bamlanivimab/etesevimab and bebtelovimab.
risk of hospitalization, 27.0% higher, RR 1.27, p = 1.00, treatment 5 of 252 (2.0%), control 2 of 128 (1.6%), combined bebtelovimab arms.
risk of hospitalization, 2.4% higher, RR 1.02, p = 1.00, treatment 2 of 125 (1.6%), control 2 of 128 (1.6%), bebtelovimab only.
recovery time, 25.0% lower, relative time 0.75, treatment 127, control 128.
relative viral load reduction, 4.0% better, RR 0.96, p < 0.001, treatment mean 3.77 (±0.21) n=125, control mean 3.62 (±0.2) n=128, day 7.
relative viral load reduction, 29.7% better, RR 0.70, p < 0.001, treatment mean 3.03 (±0.19) n=125, control mean 2.13 (±0.19) n=128, day 5.
relative viral load reduction, 15.4% better, RR 0.85, p < 0.001, treatment mean 1.43 (±0.2) n=125, control mean 1.21 (±0.2) n=128, day 3.
risk of no viral clearance, 38.6% lower, RR 0.61, p = 0.12, treatment 15 of 125 (12.0%), control 25 of 128 (19.5%), NNT 13, persistently high viral load, day 7, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Dougan et al., 12 Mar 2022, Randomized Controlled Trial, USA, preprint, 22 authors, study period 19 April, 2021 - 19 July, 2021, trial NCT04634409 (history) (BLAZE-4).
Contact: robert.gottlieb@bswhealth.org.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperBebtelovimabAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2022.03.10.22272100; this version posted March 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19. Authors: Michael Dougan, MD, PhD1; Masoud Azizad, MD2, Peter Chen, MD3; Barry Feldman, MD4; Matthew Frieman, PhD5; Awawu Igbinadolor, MD6; Princy Kumar, MD7; Jason Morris, MD8; Jeffrey Potts, MD9; Lauren Baracco, BS5; Lisa Macpherson, MSPHc10; Nicole L. Kallewaard, PhD10; Dipak R. Patel, MD, PhD10; Matthew M. Hufford, PhD10; Linda Wietecha, MSc10; Emmanuel Chigutsa, PhD10; Sarah L. Demmon, MS10; Bryan E. Jones, PhD10; Ajay Nirula, MD, PhD10; Daniel M. Skovronsky, MD, PhD10; Mark Williams, MD, FCCM, FCCP10; Robert L. Gottlieb, MD, PhD11. Affiliations: 1Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; 2Valley Clinical Trials, Northridge, CA, USA; 3Cedars–Sinai Medical Center, Los Angeles, CA, USA; 4Millennium Medical Group, Farmington Hills, MI, USA; 5University of Maryland School of Medicine, Baltimore, MD; 6Monroe Biomedical Research, Monroe, NC, USA; 7Georgetown University, Washington, DC, USA; 8Clinical Trials of Southwest Louisiana, Lake Charles, LA, USA; 9Great Lakes Research Group, Inc., Bay City, MI, USA; 10Eli Lilly and Company, Indianapolis, IN, USA. 11Baylor University Medical Center and Baylor Scott & White Research Institute, Dallas, TX, USA; Corresponding author: Robert L. Gottlieb, MD, PhD, Baylor University Medical Center and Baylor Scott & White Research Institute, Dallas, TX, USA. E-mail: Robert.Gottlieb@BSWHealth.org. Phone: +1-214-820-6856 (Office). NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 1 medRxiv preprint doi: https://doi.org/10.1101/2022.03.10.22272100; this version posted March 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . BACKGROUND: Bebtelovimab is a potent, fully human IgG1 monoclonal antibody (mAb) targeting the S-protein of SARS-CoV-2, with broad neutralizing activity to all currently known SARS-CoV-2 variants of concern, including omicron variant lineages. Specialized developmental approaches accelerated the initiation of a clinical trial designed to evaluate the efficacy and safety of bebtelovimab alone (BEB) or together with bamlanivimab (BAM) and etesevimab (ETE) delivered via slow intravenous push for the treatment of mild-tomoderate COVID-19. METHODS: This portion of the phase 2, BLAZE-4 trial (J2X-MC-PYAH; NCT04634409) enrolled 714 patients (between May and July 2021) with mild-to-moderate COVID-19 within 3 days (≤3 days) of laboratory diagnosis of SARS-CoV-2 infection. Patients at low risk for severe COVID19 were randomized 1:1:1 (double-blinded) to placebo, BEB 175 mg, or BEB 175 mg+BAM 700 mg+ETE 1400 mg (BEB+BAM+ETE). Patients at high risk for progression to severe COVID-19 were randomized 2:1 (open-label) to BEB or BEB+BAM+ETE, and a subsequent treatment arm enrolled..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit